Limits...
Effect of Lovastatin on lipid peroxidation and total antioxidant concentrations in hemodialysis patients.

Argani H, Ghorbani A, Rashtchizade N, Rahbaninobar M - Lipids Health Dis (2004)

Bottom Line: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy.Both of them, quantitatively and qualitatively, are improved by using of Lovastatin.The later would be due to enhance of TA activity.

View Article: PubMed Central - HTML - PubMed

Affiliation: Hemodialysis and Nephrology Division, Emam Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. hassanargani@hotmail.com

ABSTRACT

Background: Atherosclerosis is the main cause of mortality and morbidity in end stage renal diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for atherosclerosis, non classical risk factors, such as high lipid peroxidation and low antioxidants, also, are culprit in the pathogenesis.

Method: We tested lipid peroxidation and total antioxidant levels in forty five stable hyperlipidemic HD males (age range 40-60 years) before, after 45 and 90 days of prescription of 20 mg/day Lovastatin for three months. Malondialdehyde (MDA), as prototype of lipid peroxidation, and total antioxidants (TA) were measured by flourimetric and spectrophotometric assays, respectively.

Results: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy. These changes for HDL, VLDL and Tg after the 3 months were more obvious than 45 days of Lovastatin therapy.

Conclusion: In HD patients serum lipids and their oxidations are increased. Both of them, quantitatively and qualitatively, are improved by using of Lovastatin. The later would be due to enhance of TA activity.

No MeSH data available.


Related in: MedlinePlus

Serum lipoproteins before and after beginning of Lovastatin at the end of 1.5 and 3 months
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC420253&req=5

Figure 1: Serum lipoproteins before and after beginning of Lovastatin at the end of 1.5 and 3 months

Mentions: At the beginning of the study the mean levels of total C, Tg, LDL-C, VLDL-C, HDL-C, were 185.8 ± 48.3 mg/dl, 213.7 ± 112.4 mg/dl, 120.1 ± 48.9 mg/dl, 40.7 ± 18.9 mg/dl and 24.9 ± 11.1 mg/dl, respectively. MDA level and TA activity were 13.1 ± 3.5 nmol/ml and 0.98 ± 0.17 mmol/l, respectively (Table 1). 45 days after treatment by Lovastatin significant decrease in levels of total C (150.9 ± 32 mg/dl, p = 0.002), LDL-C (83.9 ± 38.3, p = 0.001), VLDL-C (36.6 ± 15.6 mg/dl, p = 0.001) and MDA (3.68 ± 2.6 mg/dl, p = 0.000) were observed. But serum levels of Tg (183.3 ± 78.1 mg/dl, p = 0.064) and HDL-C (29 ± 12.2 mg/dl, p = 0.17) did not change significantly. It was also a significant increase in TA level after this period of Lovastatin therapy (1.16 ± 0.29 mmol/l, p = 0.022) (fig. 1).


Effect of Lovastatin on lipid peroxidation and total antioxidant concentrations in hemodialysis patients.

Argani H, Ghorbani A, Rashtchizade N, Rahbaninobar M - Lipids Health Dis (2004)

Serum lipoproteins before and after beginning of Lovastatin at the end of 1.5 and 3 months
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC420253&req=5

Figure 1: Serum lipoproteins before and after beginning of Lovastatin at the end of 1.5 and 3 months
Mentions: At the beginning of the study the mean levels of total C, Tg, LDL-C, VLDL-C, HDL-C, were 185.8 ± 48.3 mg/dl, 213.7 ± 112.4 mg/dl, 120.1 ± 48.9 mg/dl, 40.7 ± 18.9 mg/dl and 24.9 ± 11.1 mg/dl, respectively. MDA level and TA activity were 13.1 ± 3.5 nmol/ml and 0.98 ± 0.17 mmol/l, respectively (Table 1). 45 days after treatment by Lovastatin significant decrease in levels of total C (150.9 ± 32 mg/dl, p = 0.002), LDL-C (83.9 ± 38.3, p = 0.001), VLDL-C (36.6 ± 15.6 mg/dl, p = 0.001) and MDA (3.68 ± 2.6 mg/dl, p = 0.000) were observed. But serum levels of Tg (183.3 ± 78.1 mg/dl, p = 0.064) and HDL-C (29 ± 12.2 mg/dl, p = 0.17) did not change significantly. It was also a significant increase in TA level after this period of Lovastatin therapy (1.16 ± 0.29 mmol/l, p = 0.022) (fig. 1).

Bottom Line: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy.Both of them, quantitatively and qualitatively, are improved by using of Lovastatin.The later would be due to enhance of TA activity.

View Article: PubMed Central - HTML - PubMed

Affiliation: Hemodialysis and Nephrology Division, Emam Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. hassanargani@hotmail.com

ABSTRACT

Background: Atherosclerosis is the main cause of mortality and morbidity in end stage renal diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for atherosclerosis, non classical risk factors, such as high lipid peroxidation and low antioxidants, also, are culprit in the pathogenesis.

Method: We tested lipid peroxidation and total antioxidant levels in forty five stable hyperlipidemic HD males (age range 40-60 years) before, after 45 and 90 days of prescription of 20 mg/day Lovastatin for three months. Malondialdehyde (MDA), as prototype of lipid peroxidation, and total antioxidants (TA) were measured by flourimetric and spectrophotometric assays, respectively.

Results: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy. These changes for HDL, VLDL and Tg after the 3 months were more obvious than 45 days of Lovastatin therapy.

Conclusion: In HD patients serum lipids and their oxidations are increased. Both of them, quantitatively and qualitatively, are improved by using of Lovastatin. The later would be due to enhance of TA activity.

No MeSH data available.


Related in: MedlinePlus